Subscribe To

Price Alert Latest News Economic Calendar News

PXSLY / Pharmaxis cleared to progress to Phase 2 Bone marrow cancer trial

Pharmaxis cleared to progress to Phase 2 Bone marrow cancer trial

Pharmaxis Ltd (ASX:PXS), a clinical-stage drug development company, has received positive results from data analysis of a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis. This phase 1c trial was centred on dose escalation and involved giving patients with the bone marrow cancer myelofibrosis PXS' LOX-inhibiting drug PXS-5505 for 28 days at three dosage levels. Read More

Demo Live Account See Partner Details

Content Topics

Pharmaxis

Cleared

Progress

Phase

Bone

Marrow

Cancer

Trial

Stock

PXSLY

Posted: Oct 4 2021, 23:34

Author Name: Proactive Investors

Views: 102590

PXSLY News

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

By Proactive Investors
January 30, 2022

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is targeting a potential breakthrough treatment for patients with problematic scar tissue to service unmet de

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

By Proactive Investors
January 30, 2022

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is targeting a potential breakthrough treatment for patients with problematic scar tissue to service unmet de

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

By Proactive Investors
January 30, 2022

Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study

Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is targeting a potential breakthrough treatment for patients with problematic scar tissue to service unmet de

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

By Proactive Investors
January 6, 2022

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

Pharmaxis Ltd's drug discoveries have been given a boost after the Australian government awarded two grants totalling A$1.4 million to respected scie

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

By Proactive Investors
January 6, 2022

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

Pharmaxis Ltd's drug discoveries have been given a boost after the Australian government awarded two grants totalling A$1.4 million to respected scie

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

By Proactive Investors
January 6, 2022

Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments

Pharmaxis Ltd's drug discoveries have been given a boost after the Australian government awarded two grants totalling A$1.4 million to respected scie

Pharmaxis discoveries to get a $1.4M boost to advance cancer and skin disease treatments

By Proactive Investors
January 6, 2022

Pharmaxis discoveries to get a $1.4M boost to advance cancer and skin disease treatments

Pharmaxis Ltd's drug discoveries have been given a boost after the Australian government awarded two grants totalling $1.4 million to respected scien

Pharmaxis discoveries to get a $1.4M boost to advance cancer and skin disease treatments

By Proactive Investors
January 6, 2022

Pharmaxis discoveries to get a $1.4M boost to advance cancer and skin disease treatments

Pharmaxis Ltd's drug discoveries have been given a boost after the Australian government awarded two grants totalling $1.4 million to respected scien

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.